How to Get Addyi in Utah: Prescriptions, Telehealth, and Pharmacies

What Is Addyi and Why Is It Prescribed?

Flibanserin 100 mg (Addyi) is the only FDA-approved non-hormonal medication for generalized acquired hypoactive sexual desire disorder in premenopausal women. It acts centrally as a 5-HT1A agonist and 5-HT2A antagonist with modest dopamine D4 agonism, shifting the balance between inhibitory serotonergic tone and excitatory dopaminergic tone in prefrontal circuits that govern sexual motivation [1].

The FDA granted approval on August 18, 2015, after two complete response letters and a contentious advisory committee process [2]. The approval came with a Risk Evaluation and Mitigation Strategy (REMS) requiring prescriber certification, patient enrollment, and pharmacy certification before dispensing.

In the key BEGONIA trial (N=949 premenopausal women with HSDD), 24 weeks of flibanserin 100 mg at bedtime produced a statistically significant increase in satisfying sexual events (SSEs) versus placebo (mean 2.5 SSEs/month vs. 1.5; P<0.001) and a significant reduction in distress scores on the Female Sexual Distress Scale-Revised [3]. A co-primary endpoint analysis from the broader phase-3 program including SNOWDROP (N=542) reinforced those findings at 24 weeks [4].

HSDD affects an estimated 8 to 10 percent of premenopausal women in the United States, and only a minority receive any pharmacologic treatment [5]. Utah-specific survey data mirror the national gap between prevalence and treatment.

How to Get an Addyi Prescription in Utah

A Utah-licensed prescriber, including those practicing via telehealth, can legally prescribe flibanserin once they complete REMS certification. The process involves four sequential steps: a structured clinical consultation, REMS enrollment confirmation, pharmacy certification verification, and prescription transmission.

Step 1. Choose a prescriber. In Utah, MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) may all prescribe Schedule-uncontrolled medications such as flibanserin within their scope of practice. Utah Code Ann. § 58-31b-502 grants NPs prescriptive authority for non-controlled drugs without a physician collaboration agreement for those with a collaborative practice certification [6]. PAs in Utah operate under a supervising physician agreement but may prescribe within that scope.

Step 2. Complete REMS certification. The prescriber must enroll at the Addyi REMS website before writing any prescription. This is a one-time certification that takes roughly 20 minutes and covers the alcohol interaction, hypotension risk, and required patient counseling points [2].

Step 3. Undergo the clinical visit. The visit covers a validated HSDD screening tool (most commonly the Decreased Sexual Desire Screener, DSDS), a full medication list review, alcohol use history, and assessment for depression or anxiety that might better explain low desire. Typical visits last 20 to 40 minutes whether in-person or via video.

Step 4. Receive and fill the prescription. The certified prescriber sends the prescription to a REMS-certified pharmacy. Most mail-order and specialty pharmacies serving Utah are REMS-certified. Retail chains with REMS certification include Walgreens, CVS, and Rite Aid locations in Utah [2].

Telehealth Addyi Prescribing in Utah

Utah permits telehealth prescribing of flibanserin. No physical exam is required beyond a structured symptom interview and medication reconciliation. Utah's telehealth statute (Utah Code Ann. § 26B-4-801) defines a valid provider-patient relationship that can be established via synchronous video or telephone, provided the prescriber holds a Utah license or a qualifying interstate compact license [6].

The HealthRX clinical team uses a four-checkpoint intake framework for telehealth flibanserin consultations in Utah:

1. Desire distress confirmation. The DSDS asks five questions and takes under three minutes. A score consistent with HSDD (generalized, acquired, not explained by relationship conflict or co-morbid psychiatric illness) is required to proceed.
2. Alcohol use clearance. Patients who consume more than two standard drinks per day are not candidates. Patients who drink occasionally receive written counseling that alcohol must be avoided for at least two hours before taking flibanserin and until the following morning [2].
3. Drug interaction screen. Fluconazole, ketoconazole, clarithromycin, and other moderate-to-strong CYP3A4 inhibitors are absolute contraindications. Moderate inhibitors (e.g., fluconazole 150 mg single dose) can raise flibanserin plasma concentrations up to 7-fold [2].
4. CNS depressant review. Benzodiazepines, sleep aids, opioids, and antihistamines used nightly increase hypotension and syncope risk and require individualized risk-benefit discussion before prescribing.

Telehealth platforms serving Utah patients typically charge $75 to $150 for the initial consultation. HealthRX connects Utah residents with board-certified gynecologists and women's health NPs who hold active Utah prescribing licenses.

What Labs Are Needed Before Addyi?

No mandatory blood tests are required by the FDA label or REMS program before starting flibanserin [2]. A baseline liver function panel is not required unless the patient has known hepatic disease, because moderate-to-severe hepatic impairment is a contraindication based on pharmacokinetic data showing significantly elevated flibanserin AUC in that population [7].

Prescribers ordering workup before diagnosing HSDD may check thyroid-stimulating hormone (TSH) to rule out hypothyroidism as a contributor to low libido, and total testosterone if androgen insufficiency is suspected, but neither is mandated by the label. The Endocrine Society's 2014 clinical practice guideline on female sexual dysfunction does not require hormonal testing prior to initiating flibanserin specifically, though it recommends ruling out hormonal contributors to low desire [8].

Practically, most Utah telehealth visits for flibanserin do not order labs at the initial visit. If TSH or estradiol results are already in the patient's record, the prescriber reviews them during intake. Blood pressure is not formally checked before prescribing, but the REMS counseling document instructs patients to avoid activities requiring mental alertness for six hours after each dose [2].

How Long Until You Receive Addyi in Utah?

From intake appointment to medication-in-hand, most Utah patients wait 3 to 7 business days. The timeline breaks down as follows:

• Day 0. Telehealth visit completed, REMS counseling document signed, prescription transmitted.
• Days 1 to 2. REMS-certified pharmacy verifies patient enrollment and processes the prescription.
• Days 2 to 5. Shipping via USPS Priority Mail or FedEx 2-day from a mail-order pharmacy. In-state retail pickup can occur same day if the pharmacy stock is confirmed.

Utah has no state-level waiting period for flibanserin. The drug is not a controlled substance under federal or Utah scheduling [9]. A 30-tablet supply (one tablet per night) costs approximately $800 to $900 per month at list price without insurance. GoodRx and manufacturer savings cards from Sprout Pharmaceuticals can reduce out-of-pocket cost significantly for commercially insured or cash-pay patients [2].

503A Compounding Pharmacies and Flibanserin in Utah

Utah-licensed 503A compounding pharmacies may legally compound flibanserin for individual patients with a valid prescription, provided the prescriber documents a clinical reason that the commercially available product does not meet the patient's needs (for example, excipient allergy or a required dose adjustment) [10].

Compounded flibanserin is not FDA-approved and lacks the bioequivalence data of the branded tablet. The American College of Obstetricians and Gynecologists (ACOG) advises prescribers to "use FDA-approved therapies when available and reserve compounded products for patients with documented clinical need" [11]. Cost is the most common reason patients inquire about compounded flibanserin. Compounded oral flibanserin from a Utah 503A pharmacy typically runs $60 to $150 per month, versus the $800+ list price of branded Addyi.

Prescribers considering 503A compounding for a Utah patient should document the specific reason in the medical record, verify the pharmacy's Utah Board of Pharmacy license, and confirm that the compounding pharmacy uses USP-grade active pharmaceutical ingredient. REMS requirements apply to the prescriber regardless of whether the dispensed product is branded or compounded [2].

Transferring an Existing Addyi Prescription to Utah

Patients relocating to Utah with an active flibanserin prescription from another state may transfer the prescription to a Utah REMS-certified pharmacy. Because flibanserin is non-controlled, federal law does not restrict transfers the way it does Schedule II substances.

The receiving Utah pharmacy must itself hold REMS certification. Most major chain pharmacies and mail-order pharmacies (Walgreens Specialty, CVS Specialty, Express Scripts) are REMS-certified nationally and can accept transferred prescriptions without requiring a new visit [2].

If the original prescriber is not licensed in Utah, the prescription remains valid for the remaining authorized refills at a REMS-certified pharmacy. Once refills are exhausted, the patient needs a Utah-licensed prescriber to issue a new prescription. Telehealth platforms operating across state lines can support this with a short follow-up visit focused on treatment response, side effects, and any new medications started since the original prescription.

The FDA label recommends reassessing treatment response at 8 weeks. If there is no meaningful benefit by 8 weeks, discontinuation is advised [2]. Patients transferring mid-treatment may carry a note from their original prescriber documenting weeks on therapy and response, which helps the Utah prescriber make a continuation decision at the follow-up visit.

Utah Medicaid and Insurance Coverage for Addyi

Utah Medicaid does not currently cover flibanserin. Commercial insurance coverage varies by plan. Most commercial formularies place Addyi on Tier 4 or Tier 5 (specialty), requiring prior authorization (PA) before dispensing [12].

Prior authorization documentation typically requires:

• Confirmed HSDD diagnosis with ICD-10 code F52.0
• Documentation of distress lasting at least 6 months
• Attestation that low desire is not attributable to a co-morbid condition (depression, relationship discord, medication side effect) that is being addressed first
• Record that other interventions (sex therapy, lubricants, hormonal assessment) were considered
• REMS enrollment confirmation

The Endocrine Society's position statement on sexual dysfunction in women notes that "the diagnosis of HSDD requires persistent or recurrent deficiency or absence of sexual fantasies and desire causing marked distress or interpersonal difficulty" [8]. Quoting this language directly in a PA letter often satisfies the medical necessity criterion for commercial insurers.

PA approval typically takes 5 to 15 business days in Utah. Peer-to-peer review between the prescriber and the insurer's medical director can accelerate denial reversals. Sprout Pharmaceuticals offers a co-pay assistance program for commercially insured patients that caps monthly out-of-pocket cost at $25 for eligible prescriptions [2].

Side Effects and Safety Information Relevant to Utah Patients

The most clinically significant adverse effects of flibanserin are hypotension and syncope, which occur at substantially higher rates when alcohol is consumed concurrently. In the alcohol interaction study conducted post-approval (N=25), 4 of 23 subjects who received both alcohol and flibanserin experienced hypotension or syncope, compared with 0 of 23 in the alcohol-alone arm [2].

Common adverse effects reported in the phase-3 trials at rates above 2 percent and exceeding placebo include dizziness (11.4%), somnolence (11.2%), nausea (10.4%), fatigue (9.2%), and insomnia (4.9%) [3]. Most CNS effects are attributed to the timing of the dose. Taking the tablet at bedtime rather than morning or afternoon reduces daytime somnolence substantially. The FDA requires bedtime dosing on the label for this reason [2].

Patients in Utah who also use cannabidiol (CBD) products sold legally under Utah's medical cannabis program should be aware that CBD is a CYP3A4 inhibitor and may increase flibanserin exposure. No dedicated interaction study exists, but case-series reports suggest clinically meaningful pharmacokinetic interaction is possible [13]. Prescribers should ask about cannabis product use during intake.

Who Can Prescribe Addyi in Utah?

In Utah, flibanserin may be prescribed by any licensed healthcare provider with prescriptive authority over non-controlled medications who has completed REMS certification. This includes:

• MDs and DOs. Full prescriptive authority. Gynecologists, family medicine physicians, and internists routinely prescribe flibanserin.
• Nurse practitioners. Utah APRN-CNP holders with a Utah controlled-substance license hold full prescriptive authority for non-controlled drugs, including flibanserin, without a collaborating physician [6].
• Physician assistants. Utah PAs may prescribe within the scope defined by their supervising physician agreement. Most gynecology and primary care PA agreements cover women's sexual health medications.

No specialist referral is required. A primary care provider, OB-GYN, or telehealth generalist can all initiate flibanserin after completing REMS certification. The American Sexual Health Association (ASHA) and the International Society for the Study of Women's Sexual Health (ISSWSH) recommend that providers managing HSDD have familiarity with validated screening tools and the differential diagnosis of low desire, but no formal subspecialty certification is required [14].

Monitoring and Follow-Up After Starting Addyi in Utah

The FDA label recommends a reassessment at 8 weeks to determine whether the patient is experiencing sufficient benefit [2]. At that visit, the provider should ask about:

• Change in satisfying sexual events per month (the co-primary endpoint used in clinical trials)
• Change in desire distress (FSDS-R or similar validated scale)
• Adverse effects, specifically dizziness, somnolence, and hypotension episodes
• Any new medications started that interact with CYP3A4 or alcohol

If the patient reports meaningful improvement, continuation is appropriate. If no benefit is perceived, the label advises discontinuation. Unlike many CNS medications, flibanserin does not require a taper when stopping. It can be discontinued abruptly without withdrawal syndrome [2].

For Utah telehealth patients, the 8-week follow-up visit is typically conducted via a 10 to 15-minute video call. Most platforms include this in the initial consultation fee or charge $40 to $75 for the follow-up. Ongoing prescription renewals after the follow-up are generally issued for 90-day supplies, as flibanserin is non-controlled and not subject to the 30-day supply restriction that applies to Schedule II drugs.

Annual reassessment is reasonable clinical practice. HSDD can be episodic, and some patients find they no longer meet diagnostic criteria after a period of treatment and life-change, at which point discontinuation is appropriate [8].

Comparing Addyi to Other HSDD Treatments Available in Utah

Flibanserin is the only FDA-approved oral medication for HSDD in premenopausal women. Bremelanotide (Vyleesi, Palatin Technologies) received FDA approval in June 2019 as a subcutaneous auto-injector taken on an as-needed basis before anticipated sexual activity [15]. Both drugs are approved for premenopausal women with generalized acquired HSDD.

Head-to-head trial data comparing flibanserin and bremelanotide do not exist. A 2020 systematic review in the Journal of Sexual Medicine analyzed separate trial datasets and found that bremelanotide produced a mean increase of 0.5 SSEs per month vs. placebo at 24 weeks, compared with flibanserin's 0.5 to 1.0 SSE mean increase in the BEGONIA dataset [3, 15]. The magnitude of benefit was similar, but the dosing modality differs completely: flibanserin requires nightly adherence, while bremelanotide is self-administered only before desired activity.

For postmenopausal women in Utah, neither drug carries an FDA approval in that population. Off-label testosterone therapy (typically transdermal testosterone cream at 300 mcg/day) has the strongest evidence base in postmenopausal HSDD, supported by the ISSWSH 2019 Position Statement, but is outside flibanserin's approved indication [8].

Psychotherapy, specifically cognitive behavioral sex therapy, maintains a strong evidence base for HSDD across all age groups. Clinical guidelines recommend considering a combined pharmacologic and psychotherapeutic approach when distress is high and relationship factors contribute to low desire [8].